Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07467993 | Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia | PHASE2 | RECRUITING | 142 | — | — | Mar 16, 2026 | Apr 22, 2027 | May 14, 2026 | 7 | United States |
PANSS is a 30-item rating scale used to assess the positive, negative, and general psychopathy symptoms of schizophrenia. PANSS total score ranges from 30 to 120 , where a higher score indicates greater severity.
| Arm | Type | Description |
|---|---|---|
| GXV813 | EXPERIMENTAL | GXV813 administered orally. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| GXV813 | DRUG | GXV813 administered orally. |
| Placebo | DRUG | Placebo administered orally. |
Inclusion Criteria: 1. Participant is aged 18 to 65 years, inclusive, at screening 2. Participant is capable of providing informed consent 3. Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Associat...